Literature DB >> 23862718

Cereblon expression in multiple myeloma: not ready for prime time.

Laurence Lodé1, Martine Amiot, Sophie Maiga, Cyrille Touzeau, Audrey Menard, Florence Magrangeas, Stephane Minvielle, Catherine Pellat-Deceunynck, Marie-Christine Bene, Philippe Moreau.   

Abstract

Entities:  

Keywords:  drug resistance; multiple myeloma; prognostic factors

Mesh：

Substances：

Year:  2013        PMID： 23862718     DOI： 10.1111/bjh.12478

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  6 in total

1.  Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma.

Authors:  Bachisio Ziccheddu; Giulia Biancon; Filippo Bagnoli; Chiara De Philippis; Francesco Maura; Even H Rustad; Matteo Dugo; Andrea Devecchi; Loris De Cecco; Marialuisa Sensi; Carolina Terragna; Marina Martello; Tina Bagratuni; Efstathios Kastritis; Meletios A Dimopoulos; Michele Cavo; Cristiana Carniti; Vittorio Montefusco; Paolo Corradini; Niccolo Bolli
Journal:  Blood Adv       Date:  2020-03-10

Review 2.  Cereblon in health and disease.

Authors:  Hyoung Kyu Kim; Tae Hee Ko; Bayalagmaa Nyamaa; Sung Ryul Lee; Nari Kim; Kyung Soo Ko; Byoung Doo Rhee; Chul-Seung Park; Bernd Nilius; Jin Han
Journal:  Pflugers Arch       Date:  2016-06-24       Impact factor: 3.657

3.  Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.

Authors:  Shang-Yi Huang; Chung-Wu Lin; Hsiu-Hsia Lin; Ming Yao; Jih-Luh Tang; Shang-Ju Wu; Yao-Chang Chen; Hsiao-Yun Lu; Hsin-An Hou; Chien-Yuan Chen; Wen-Chien Chou; Woei Tsay; Sheng-Je Chou; Hwei-Fang Tien
Journal:  Ann Hematol       Date:  2014-04-01       Impact factor: 3.673

4.  Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.

Authors:  Phoebe A Huang; Shaunna L Beedie; Cindy H Chau; David J Venzon; Sheryl Gere; Dickran Kazandjian; Neha Korde; Sham Mailankody; Ola Landgren; William D Figg
Journal:  Sci Rep       Date:  2019-10-16       Impact factor: 4.379

5.  Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy.

Authors:  A Thakurta; A K Gandhi; M F Waldman; C Bjorklund; Y Ning; D Mendy; P Schafer; A Lopez-Girona; S Lentzsch; S A Schey; Y Calle; R Chelliah; R Z Orlowski; A Madan; H Avet-Loiseau; R Chopra
Journal:  Leukemia       Date:  2013-10-29       Impact factor: 11.528

6.  Prediction Model for Cereblon Expression in Bone Marrow Plasma Cells Based on Blood Markers in Multiple Myeloma Patients.

Authors:  Byung-Hyun Lee; Ka-Won Kang; Min Ji Jeon; Eun Sang Yu; Dae Sik Kim; Se Ryeon Lee; Hwa Jung Sung; Yong Park; Chul Won Choi; Byung Soo Kim
Journal:  Front Oncol       Date:  2021-07-14       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.